CA-VELODYNE-LIDAR,-INC.
16.6.2020 14:02:13 CEST | Business Wire | Press release
Velodyne Lidar, Inc. today announced a multi-year partnership agreement with Outsight, the company that is a leading innovator in Smart Cities monitoring. Outsight uses Velodyne Lidar sensing technology in its 3D Semantic Camera system that helps businesses and governments improve the analysis and management of people flow and assets in large crowded environments.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200616005074/en/
Velodyne’s lidar sensors enable the 3D Semantic Camera solution to capture 3D data and track people and objects in a way that preserves anonymity and trust. The autonomous system merges lidar data capture with RGB color data with an embedded AI processing unit to create a premises-wide, detailed situational understanding of facilities, such as airports, shopping malls and train stations.
In a Smart City application, 3D Semantic Cameras provide operators of public spaces access to real-time data and analysis without compromising private data protection. The solution is being deployed at Paris-Charles de Gaulle airport to optimize the passenger journey, improve queue and asset management, and enhance compliance and safety.
Outsight’s 3D Semantic Cameras can also be deployed to support social distancing and public health. The solution can track individuals based on selected criteria, such as lack of physical distancing, high temperature or not wearing a mask, without having to visually identify them. The Outsight device then can alert the operator when an abnormal event is detected, saving time and resources while optimizing crowd flows.
“Velodyne’s lidar sensors play an essential role in helping our platform capture, process and understand congested environments so operators can work to increase operational efficiency and security,” said Cedric Hutchings, CEO, Outsight. “The Velodyne lidar sensors allow us to track each individual person and object with centimeter-level precision. They enable our solutions to precisely monitor movements, velocity and interactions between all persons and objects in real time.”
“Outsight uses Velodyne’s lidar technology to bring a totally new approach to real-time situational awareness on what’s happening in busy spaces, such as airports,” said Jon Barad, Vice President of Business Development, Velodyne Lidar. “Their system helps organizations move away from traditional surveillance to create a more intelligent infrastructure that tracks people and objects in a more reliable way.”
About Velodyne Lidar
Velodyne provides smart, powerful lidar solutions for autonomy and driver assistance. Headquartered in San Jose, Calif., Velodyne is known worldwide for its portfolio of breakthrough lidar sensor technologies. Velodyne’s founder, David Hall, invented real-time surround view lidar systems in 2005 as part of Velodyne Acoustics. Mr. Hall’s invention revolutionized perception and autonomy for automotive, new mobility, mapping, robotics, and security. Velodyne’s high-performance product line includes a broad range of sensing solutions, including the cost-effective Puck™, the versatile Ultra Puck™, the autonomy-advancing Alpha Prime™, the ADAS-optimized Velarray™, and the groundbreaking software for driver assistance, Vella™.
About Outsight
Outsight develops a 3D Semantic Camera, a revolutionary kind of sensor that brings Full Situation Awareness to Smart Machines and Monitoring Solutions. This sensor combines software and hardware to create sensor innovations such as remote material identification with comprehensive real-time 3D data processing. This technology provides an unprecedented and cost-efficient ability for systems to perceive, understand and ultimately interact with their surroundings in real time. Outsight believes in making a smarter and safer world by empowering cars, drones, robots and monitoring solutions with the superhuman capabilities provided by their 3D Semantic Camera. Their international team of scientists and engineers operates out of Paris, Helsinki and San Francisco.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200616005074/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom